HIV感染者猴痘预防和治疗临时指南——美国,2022年8月
本临时指南针对HIV感染者猴痘的预防与治疗提出建议。在已知HIV状态的MSM猴痘患者中,28%-51%合并HIV感染。CDC可通过研究性药物方案提供tecovirimat作为一线治疗,未发现与抗逆转录病毒治疗(ART)的明确药物相互作用;如有指征,可考虑使用JYNNEOS疫苗进行暴露前和暴露后预防。尽管HIV感染者猴痘数据有限,及时诊断、治疗和预防可能降低不良结局风险并限制猴痘传播。预防和治疗建议将随新信息更新。
要点
- 在已知HIV状态的MSM猴痘患者中,28%-51%合并HIV感染。
- tecovirimat作为一线治疗可通过CDC研究性药物方案获得,未发现与ART的明确药物相互作用。
- 如有指征,可考虑使用JYNNEOS疫苗进行暴露前和暴露后预防。
核心结论
- 尽管HIV感染者猴痘数据有限,及时诊断、治疗和预防可能降低不良结局风险并限制猴痘传播。
- 预防和治疗建议将随更多信息更新。
研究设计与样本
- 美国CDC发布的临时指南,基于2022年5月以来全球猴痘疫情监测数据及文献综述。
- 猴痘于2022年8月4日在美国被宣布为公共卫生紧急事件。
主要发现
- 自2022年5月以来,WHO报告全球约25,000例猴痘病例,疫情中心在欧洲和北美。
- 当前疫情对男男性行为者(MSM)影响尤为严重。
- 来自欧盟、英格兰和美国的监测数据显示,在已知HIV状态的MSM猴痘患者中,28%-51%合并HIV感染。
关键数值与推荐
- tecovirimat作为一线治疗可通过CDC研究性药物方案以同情用药方式获得。
- 未发现明确药物相互作用会妨碍tecovirimat与HIV抗逆转录病毒治疗(ART)合用。
- 如有指征,可考虑使用JYNNEOS疫苗进行暴露前和暴露后预防。
临床怎么用
- 对已知HIV状态的MSM猴痘患者,应了解其HIV感染比例可达28%-51%。
- tecovirimat可作为一线治疗,通过CDC研究性药物方案获取,未发现与ART的明确药物相互作用。
- 如有指征,可考虑使用JYNNEOS疫苗进行暴露前和暴露后预防。
- 及时诊断、治疗和预防可能降低不良结局风险并限制猴痘传播。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monkeypox virus, an orthopoxvirus sharing clinical features with smallpox virus, is endemic in several countries in Central and West Africa. The last reported outbreak in the United States, in 2003, was linked to contact with infected prairie dogs that had been housed or transported with African rodents imported from Ghana (1). Since May 2022, the World Health Organization (WHO) has reported a multinational outbreak of monkeypox centered in Europe and North America, with approximately 25,000 cases reported worldwide; the current outbreak is disproportionately affecting gay, bisexual, and other men who have sex with men (MSM) (2). Monkeypox was declared a public health emergency in the United States on August 4, 2022.† Available summary surveillance data from the European Union, England, and the United States indicate that among MSM patients with monkeypox for whom HIV status is known, 28%-51% have HIV infection (3-10). Treatment of monkeypox with tecovirimat as a first-line agent is available through CDC for compassionate use through an investigational drug protocol. No identified drug interactions would preclude coadministration of tecovirimat with antiretroviral therapy (ART) for HIV infection. Pre- and postexposure prophylaxis can be considered with JYNNEOS vaccine, if indicated. Although data are limited for monkeypox in patients with HIV, prompt diagnosis, treatment, and prevention might reduce the risk for adverse outcomes and limit monkeypox spread. Prevention and treatment considerations will be updated as more information becomes available.
引用
- O'Shea J, Filardo TD, Morris SB, et al. Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35951495. doi:10.15585/mmwr.mm7132e4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。